Identification of the ovine mannose receptor and its possible role in Visna/Maedi virus infection
- Helena Crespo†1,
- Ramsés Reina†1,
- Idoia Glaria1,
- Hugo Ramírez1, 4,
- Ximena de Andrés1,
- Paula Jáuregui1,
- Lluís Luján2,
- Luisa Martínez-Pomares3,
- Beatriz Amorena1 and
- Damián F de Andrés1Email author
© Crespo et al; licensee BioMed Central Ltd. 2011
Received: 25 November 2010
Accepted: 27 January 2011
Published: 7 February 2011
This study aims to characterize the mannose receptor (MR) gene in sheep and its role in ovine visna/maedi virus (VMV) infection. The deduced amino acid sequence of ovine MR was compatible with a transmembrane protein having a cysteine-rich ricin-type amino-terminal region, a fibronectin type II repeat, eight tandem C-type lectin carbohydrate-recognition domains (CRD), a transmembrane region, and a cytoplasmic carboxy-terminal tail. The ovine and bovine MR sequences were closer to each other compared to human or swine MR. Concanavalin A (ConA) inhibited VMV productive infection, which was restored by mannan totally in ovine skin fibroblasts (OSF) and partially in blood monocyte-derived macrophages (BMDM), suggesting the involvement of mannosylated residues of the VMV ENV protein in the process. ConA impaired also syncytium formation in OSF transfected with an ENV-encoding pN3-plasmid. MR transcripts were found in two common SRLV targets, BMDM and synovial membrane (GSM) cells, but not in OSF. Viral infection of BMDM and especially GSM cells was inhibited by mannan, strongly suggesting that in these cells the MR is an important route of infection involving VMV Env mannosylated residues. Thus, at least three patterns of viral entry into SRLV-target cells can be proposed, involving mainly MR in GSM cells (target in SRLV-induced arthritis), MR in addition to an alternative route in BMDM (target in SRLV infections), and an alternative route excluding MR in OSF (target in cell culture). Different routes of SRLV infection may thus coexist related to the involvement of MR differential expression.
Visna/maedi virus (VMV) and caprine arthritis encephalitis virus (CAEV) belong to the small ruminant lentivirus (SRLV) group, within the non-oncogenic lentivirus genus of the Retroviridae family, which includes the human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine infectious anaemia virus (EIAV). Lentiviruses have been classified attending to tropism into those that replicate in macrophages and CD4 T lymphocytes (HIV, FIV, BIV), leading to a decreased T cell number immunodeficiency syndrome, and those that replicate in macrophages but are unable to infect T lymphocytes (SRLV and EIAV). SRLVs infect sheep and goats, and cause, after a variable asymptomatic period, a slow progressive and invariably fatal disease affecting lungs, central nervous system, carpal joints, and/or mammary gland [1, 2].
Although different reports have described in vivo infection in cells from mammary epithelium, third eye lid, bone marrow, male reproductive tract, central nervous system and carpal joints, the main target cells for SRLVs in vivo appear to be the monocyte/macrophage lineage. In vitro, viral production has been achieved in a wide spectrum of cell types, synovial membrane and choroid plexus cells being the most commonly used [3, 4]. Virus entry has been also detected in cells of heterologous origin such as 293-T human cell line but not in Chinese hamster ovary (CHO) cells even under co-culture conditions, likely due to the absence of a compatible receptor as proposed previously . Like other enveloped viruses, SRLVs enter the host cell by interaction of its envelope (ENV) glycosylated protein (gp135) with cellular receptor(s), allowing the fusion of the virus with the target cell membrane . Studies aimed to identify the SRLV cellular receptor have proposed different candidate molecules, including a 30 kDa membrane-associated proteoglycan substituted with a chondroitin sulphate glycosaminoglycan chain(s) ; MHC class II molecules, which incubated with VMV inhibit viral infection, even though infection is not inhibited by class II-specific antibodies ; CD4 and CXCR4 molecules, which have been proposed as optional auxiliary components of a VMV receptor (or receptor complex) that facilitate VMV-mediated membrane fusion events ; and a complex formed by three membrane proteins of 15, 30 and 50 kDa identified as a Visna binding protein . Nevertheless, none of these molecules has been established as the main essential receptor, an issue which has stimulated research on alternative candidates.
HIV infection of CD4 T cells has been impaired by C-type lectins (such as Concanavalin A, ConA), whose binding to carbohydrate molecules prevents cell fusion and viral entry in culture due to the blockade of ENV . Other lectins anchored to the cell membrane (C-type), such as the mannose receptor (MR) family , have an affinity for the glycosylated moieties present in the surface of many pathogens. The MR is present in cells such as monocyte/macrophages, endothelial cells, perivascular microglia, kidney mesangial cells [13, 14], tracheal smooth muscle cells , Langerhans cells  and retinal pigment epithelium .
As described in humans, mice, swine and cattle, [18–20], MR is a 180-kDa transmembrane protein with five regions: a cysteine rich ricin-type amino-terminal region, a fibronectin type II repeat, eight tandem C-type lectin carbohydrate-recognition domains (CRD), a transmembrane region, and a cytoplasmic carboxy-terminal tail. The CRD domains, and more specifically CRD4 and CRD5 are essential to recognize mannose, fucose and N-acetyl glucosamine residues. MR recognizes the surface of pathogens and is involved in phagocytosis  and endocytosis, mediating antigen processing and presentation, cell migration, intracellular signalling, and pro-inflammatory and anti-inflammatory cytokine production . This receptor is able to bind bacteria, yeast, parasites, and viruses, and links innate to acquired immunity . Blocking the macrophage MR with ligands such as mannan or D-mannose leads to a decreased HIV entry . This study determines the role of mannose-specific lectins on VMV infection and syncytium formation and identifies the ovine MR and its role as an alternative SRLV receptor.
Materials and methods
Viruses and cells
Primary cultures of ovine skin fibroblasts (OSF), ovine choroid plexus (OCP) cells, goat synovial membrane (GSM) cells, and goat choroid plexus (GCP) cells, were obtained from SRLV-seronegative animals (tested by ELITEST, Hyphen Biomed; Neuville-Sur-Oise, France) and grown in DMEM medium supplemented with 10% foetal bovine serum and 1% antibiotics/antimycotics mix (Invitrogen, Barcelona, Spain). Chinese hamster ovary (CHO) cells, known to be non-permissive to SRLV infection , were grown in F-Ham 12 medium supplemented with 10% foetal bovine serum (Invitrogen). CHO cells permanently transfected with murine MR (kindly provided by Dr Luisa Martinez-Pomares, University of Nottingham, UK)  were maintained in F-Ham 12 medium with geneticin (0.5 mg/mL) and also used in infection assays. Blood monocyte-derived macrophages (BMDM) from SRLV-free sheep were obtained by culturing peripheral blood mononuclear cells (PBMC) for 9-days in RPMI 1640 containing GlutaMAX™ I and 25 mM HEPES (Invitrogen) supplemented with 10% foetal lamb serum (Invitrogen), 10 mM sodium pyruvate (Invitrogen), 1% non-essential amino acids (Sigma, Steinheim, Germany), 1% vitamins (Sigma), 50 μM 2-mercaptoetanol (Sigma), and granulocyte macrophage colony-stimulating factor (GM-CSF; kindly provided by Dr Gary Entrican, Moredun Institute, UK) at a concentration of 10 ng/mL.
The EV1 strain  was used for in vitro VMV infection assays of BMDM, OSF and GSM cells. Strains EV1, 496  and the infectious clone Kv1772  were used for in vitro infection of CHO and CHO-MR cells. All the infections were performed using 0.1 TCID50/cell.
Amplification, cloning and sequencing of the ovine mannose receptor
Oligonucleotide sequences used in the PCRs performed in this study and amplicon length.
Oligonucleotides 5'- 3'
Actin 663 Fw
Actin 769 Rv
qPCR (p17 EV1)
Inhibition of viral infection in ConA treated cultures
To evaluate the effects of ConA on viral infection and production, virus (strain EV1) was first preincubated for 60 min at 37°C either with ConA (50 μg/mL), ConA and mannan (1 mg/mL), mannan or medium alone before addition to the cell preparations. OSF and BMDM in DMEM supplemented with 2% FBS or macrophage medium, respectively, were incubated in duplicated 24-well microplates for 1 h with the treated or untreated virus inoculum. Wells were washed with PBS to remove residual inoculum and medium containing lectin (ConA) and/or inhibitor (mannose-rich mannan) was added to a final volume of 1 mL per well. Cells from one plate were collected 16 h post infection (pi) and DNA extracted in order to quantify proviral load. Supernatants from the second plate were collected at day 7 pi, when cytopathic effect (syncytia) was evident in untreated cell cultures (control). Experiments were done in triplicate and repeated three times.
A luciferase assay was performed to ensure that Concanavalin A did not affect viral basal transcription and, as a consequence, viral production. Briefly, 105 cells/well in 24-well microplates were transfected at a ratio of 1:8 (μg DNA: μL Lipofectamine) using the following plasmids: pGL4.10 [luc2] (Promega) as negative control; pGL4.13 [luc2/SV40] (Promega), which contains the SV40 promoter as positive control, and pGL4/U3-KV1772 containing the LTR U3 region. Cells were co-transfected with plasmid pRL-SV40 carrying the SV40 promoter and the Renilla reniformes luciferase gene as an endogenous control of transfection and after 4 h cells were treated with ConA, ConA and virus (EV1), or medium alone. Following 24 h, cells were lysed with Cell Culture Lysis Reagent 5 × (Promega) and luminescence measured using the Dual-Glo™ Luciferase Assay System (Promega). Luminescence units were normalized to the total protein present in each sample, which was quantified by the Bradford assay (BioRad, Madrid, Spain). Firefly luciferase activity was normalized to renilla luciferase activity. Results were expressed as luciferase units/ng of the total protein of each sample. Each experiment was done in triplicate and was repeated three times.
Inhibition of syncitium formation by Concanavalin A in env-transfected cultures
To test whether glycosylated ENV mediates cell fusion allowing syncytium formation in the absence of virus, ovine skin fibroblasts (OSF) were transfected with pN3-env plasmid (pN3 with VMV env gene encoding the precursor protein gp150 ), using Lipofectamine (Invitrogen) at a ratio of 1:6 (DNA: Lipofectamine 2 mg/mL) and following manufacturer's instructions. ENV-containing transformants were selected in the presence of geneticin (0.5 mg/mL of medium). Empty plasmid (pN3) was used as negative control. To determine the possible ConA-mediated inhibitory effect, ConA (50 μg/mL) was added 5, 24 and 48 h following transfection. Syncytium formation was evaluated by optical microscopy up to 72 h pi, after Giemsa staining. Experiments were repeated twice.
Blocking of MR by mannan
Different concentrations of mannan (4, 2, 1, 0.5, 0.25 and 0.125 mg/mL) were administered to cultured OSF (negative control), GSM cells and blood monocyte-derived macrophages (BMDM, 105 cells/well in two 24-well microplates). Following incubation (30 min at 37°C), the virus (Ev1) was added (0.1 TCID50/cell) and cells were cultured for 16 h. After washing in PBS, one plate was used for DNA extraction and provirus quantification (q-PCR). For RT activity determinations, the second plate was further incubated until day 7, when syncytia appeared in untreated cells. These blocking experiments were repeated three times.
Real time PCRs
A real time PCR technique (q-PCR) was used to determine proviral DNA for quantifying viral entry-integration upon ConA and mannan treatments 16 h pi. Briefly, OSF, GSM cells and BMDM (105 cells/well) from the ConA and/or mannan experiments (see below) were washed and fresh medium was added. Cells were harvested and DNA extracted with Qiamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. GAG (p17) segments were quantified by q-PCR as described previously  using ovine DNA from VMV infected cultures and oligonucleotides reported in Table 1. Results were expressed as provirus copy number/ng DNA. Tests were carried out in duplicate and repeated three times.
Expression of MR was quantified using β-actin as a housekeeping gene by substracting the corresponding ΔCt value from that obtained in MR using cDNA from BMDM, GSM, OSF, CHO or CHO-MR cultured cells. Specific primers for amplification of the ovine β-actin and the CDR4-CDR5 region of ovine MR are shown in Table 1.
Reverse Transcriptase (RT) activity assay
RT activity was measured in cell culture supernatants according to the manufacturer's instructions (HS-Lenti RT Activity kit, Cavidi, Uppsala, Sweden) as an indicator of productive infection. The signal intensity thus obtained was used to produce a standard curve in order to quantify the virus, using as reference standard serial dilutions of the same viral strain titrated by the classical Reed-Muench method . Experiments were done in duplicate and repeated at least twice.
Western blot and ICC
OSF, CHO, CHO-MR and GSM cell lysates (40 μg) were used in Western blot. A rabbit anti-human MR polyclonal undiluted serum (cat. No. ab64693 Abcam, Cambridge, UK) and two mouse anti-human MR monoclonal antibody reagents (clones 8 and 15. Personal communication, Luisa Martinez-Pomares, University of Nottingham, UK) were used as primary antibodies at a dilution of 1/100. Anti-rabbit or anti-mouse (Thermo Scientific, Erembodegem, Belgium) peroxidase-labelled secondary antibodies were employed accordingly at a dilution of 1/2000. The reaction was developed using Supersignal West Pico Chemiluminiscent substrate (Thermo Scientific). The same cells were also used following standard ICC protocols. Briefly, cells were washed in PBS and fixed in methanol:acetone (1:1) for 5 min. In the case of BMDM, an additional peroxidase blocking step was carried out using 5% H2O2 in methanol for 5 min. Following washing, cells were blocked for 1 h using 2.5% casein and 5% lamb serum. Primary antibody was added undiluted (in the case of monoclonal antibodies) or diluted in PBS containing 1.25% casein. After washing, anti-rabbit or anti-mouse peroxidase-labelled secondary antibodies were added at a 1/2000 dilution. The reaction was developed with diaminobenzidine (DAB).
The normal distribution of the data was confirmed by Shapiro-Wilks and Kolmogorov-Smirnov tests. The absorbance values between different treatments were compared by Student's t-test for related samples. Data obtained from real time PCR were analysed by Wilcoxon non-parametric test for related samples.
GenBank accession number
The assembled complete ovine MR sequence was submitted to GenBank and given accession number HM099914.
Characterization of the ovine mannose receptor (MR) encoding sequence and comparison with other MRs
Similarity values (%) between ovine MR predicted amino-acid sequence with that from human, swine and bovine species.
Domain of ovine MR
Cystein rich domain
TM + cytoplasmic tail
Presence of ovine MR transcripts
Relative MR transcripts expression in different cell types.
100 × 2-ΔCt
Effect of the soluble lectin Concanavalin A on VMV infection and syncytium formation
Evaluation of syncytium formation by optical microscopy in pN3-Env and pN3 transfected OSF cells following Concanavalin A addition at different time points.
Syncytium formation evaluation
ConA addition time points (h)
pN3-ENV transfected OSF
pN3 transfected OSF
Mannan blocking of VMV infection
Under the hypothesis that GSM cells and BMDM (and not OSF) express MR on the cell membrane, we assessed the role of MR in VMV infection using GSM cells, BMDM, and OSF by a mannan-mediated blocking approach.
Results compatible with these observations were obtained when studying viral production (RT activity in culture supernatants) 7 days pi. About 4 and 2.5 fold reduction in RT activity was observed in GSM cells (P < 0.0001) and BMDM (P < 0.05), respectively (Figure 3B). The effect was dependent on mannan concentration, decreasing beyond 2 mg/mL. Finally, the addition of mannan to OSF cultures, even at high concentrations (1-4 mg/mL), did not alter the production of virus (P > 0.05), as these cells were lacking MR transcripts, which strongly suggests lack of MR protein.
Altogether, these results indicate that the ovine MR was expressed in at least two cell types (GSM cells and BMDM) susceptible to VMV infection, but not in OSF.
VMV infection via heterologous MR
The role of innate immunity is gaining interest in the field of lentiviral infections [33, 34]. An important component of innate immunity is the MR (CD206), a group VI C-type lectin, present at the cell surface and endosomes . This study identifies the ovine MR genetic characteristics, the corresponding nucleotide and deduced amino acid sequences and the putative protein structure, all of which were found very close to those found in other mammals [35, 36]. Expression of the ovine MR is being attempted at present through transfection of SRLV non-permissive cells.
In the host, differences in MR oligomerization , heterogeneity of MR N-glycosylation , as well as variation in individual genetic makeup  and health status  may account for differences in MR expression. Like in other species, the ovine MR expression differed among cell types, mRNA specific transcripts being present in macrophages (BMDM) and synovial membrane (GSM) cells, but not in skin fibroblasts (OSF). In SRLV pathogenesis, GSM cells are known to be infected in vivo  and if these cells do differentially express MR on the cell surface in vivo as they do in vitro, MR could represent an entry pathway of ENV-mannosylated viruses through carpal joint infection.
The polyclonal reagent available to detect MR protein expression was produced against a 57-amino acid peptide of the human MR, but the limited size of this peptide (about 3.9% of the whole MR protein) and sequence differences (12 mismatches) between this human MR peptide and the homologous peptide of ovine origin may have led to the evident lack of cross-reactivity of the polyclonal reagent with the ovine MR. In contrast, this polyclonal antibody reacted with mouse MR (with 16 mismatches in the peptide region compared to human MR). The kind and site of amino acid substitutions may account for the differences in cross-reactivity of the polyconal reagent to the ovine vs. the mice peptide.
Evidence of VMV infection in CHO cells transfected with MR (from species like mice) supports the hypothesis that MR expression is sufficient in vitro for VMV infection in particular cell types. In a previous work  CHO/mouse somatic cell hybrid lines became permissive to SRLV if they included mouse chromosome 2 or 4. The finding that mouse chromosome 2 contains the MR gene, originally named Mcr in that species , may explain this finding and suggests that the involvement of the membrane associated C-type lectin DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) in this permissiveness (and not that of MR) could be excluded, since DC-SIGN is encoded by chromosome 8 (and not chromosomes 2 or 4). Similarly in our study, the involvement of DC-SIGN was unlikely, since dendritic cells were not used. However, redundant or alternative pathways of virus capture via lectins may coexist .
The observation that CHO cells become infected, upon transfection with MR from species not susceptible to VMV (mice), may indicate a non species-specific viral interaction with the MR. However, the CHO-MR cells infection by VMV was not productive, indicating that subsequently to viral integration, factors involved in viral production appear to differ when comparing CHO-MR with GSM cells (expressing MR), the latter being capable of productive infection.
There must be routes of virus entry into skin fibroblasts (OSF) other than mannose binding lectins, as in these cells blockade of infection by mannan did not take place but a productive VMV infection was observed. Accordingly, OSF appeared to bind, via a yet unidentified receptor different from MR, ENV viral protein glycosylated residues, taking into account the need of ENV glycosylated residues for cell fusion , and the observation that viral replication was strongly inhibited in these cells by ConA and restored upon addition of mannan (likely by mannan binding to ConA). This ConA-mediated inhibition of virus entry and syncytium formation is in agreement with results in human cells using different carbohydrate-binding agents and HIV-1 strains .
The macrophages (BMDM) used in this study represent another category of cells, which express MR transcripts but appear to produce at least two types of VMV receptors, MR and an additional unknown receptor. Mannan, when added to the virus preparation, abrogated ConA effects but only partially in these cells, according to RT activity and provirus quantification. Furthermore, when mannan was added to the cells, it inhibited infection (as it occurred in GSM cells), but only partially. MR has been proposed in different species as a main virus binding site in particular cells  (this might apply to GSM cells used in this study) and/or an auxiliary molecule in other cells (this would apply to BMDM employed in this work). In non-phagocytic cells, MR is not acting as a professional phagocytic receptor, since it does not lead to clearance of virus . Accordingly, in our study the VMV entry into GSM cells via MR subsequently led to a productive infection. However in human cells such as macrophages, results on significance of MR-mediated HIV-1 endocytosis are inconclusive . This may be due in part to the fact that lentiviruses such as HIV-1 bind cells at least via two independent pathways that may coexist in macrophages, the currently accepted infectious route by plasma membrane protein receptors and the route mediated by the endocytic MR, through which HIV-1 epitopes may be subjected to exogenous MHC class I presentation (cross-presentation) . If this applies to the VMV model, the second route would not be present in skin fibroblasts (OSF), as they lacked MR transcripts and were not susceptible to mannan-mediated blocking, but would exist in GSM cells and BMDM.
However, caution should be taken when studying MR expression in BMDM, as it may vary along the individual's life, having implications in pathogenesis. Based on the macrophage phenotype classification in subclinical vs. clinical stages  and according to this and our previous studies , macrophages of SRLV asymptomatic sheep (such as the BMDM tested in this study) would exhibit increased B7 transcript production, whereas those of clinically affected sheep would be expected to have an increased MR expression and viral infection. The known downregulation of B7 molecule expression  and a Th2-biased antibody response to the viral infection  occurring in VMV clinical disease, including arthritis , would be compatible with an upregulation of MR expression in particular target organs such as carpal joints. Antibodies against MR are currently being developed for immunohistochemical studies at different stages of VMV infection.
Besides the cellular receptor, the genetic makeup of the virus may determine the virus-cell interactions, since the number and distribution of ENV amino acids susceptible to mannosylation, may affect viral entry through membrane lectins and consequently the viral production and appearance of disease. Further studies on ENV composition and viral entry are warranted.
In conclusion, we report in vitro studies demonstrating that concerning viral entry there are at least three main patterns in target cells capable of generating a productive infection: i) particular cell types such as synovial membrane (GSM) cells may use MR as a VMV main infection route; ii) other cells such as fibroblasts (OSF) use a route other than MR to bind the glycosylated ENV allowing the virus entry to the cell; and iii) there are cells like macrophages (BMDM), a classical SRLV target, that use MR and an additional receptor for VMV entry. The three cell types may be used as in vitro models to explore the mechanisms and relative relevance of the different entry routes in VMV infections and provide the basis for studies in vivo, on tropism, viral receptors and MR expression aimed to understand viral pathogenesis and host progression from asymptomatic to clinical stages.
This work was supported by project CICYT Nos. AGL2007-66874-C04-01/GAN and AGL2010-22341-C04-01. We acknowledge the Public University of Navarra and CSIC for fellowships and contract (HC and RR). We greatly acknowledge Dr Barbara Blacklaws for supplying the strain EV1 and Dr Gary Entrican for kindly providing the ovine GM-CSF reagent.
- Carey N, Dalziel RG: The biology of maedi-visna virus--an overview. Br Vet J. 1993, 149: 437-454.View ArticlePubMedGoogle Scholar
- Clements JE, Zink MC: Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev. 1996, 9: 100-117.PubMed CentralPubMedGoogle Scholar
- Andresdottir V, Tang X, Agnarsdottir G, Andresson OS, Georgsson G, Skraban R, Torsteinsdottir S, Rafnar B, Benediktsdottir E, Matthiasdottir S, Arnadottir S, Hognadottir S, Palsson PA, Petursson G: Biological and genetic differences between lung- and brain-derived isolates of maedi-visna virus. Virus Genes. 1998, 16: 281-293. 10.1023/A:1008030706308.View ArticlePubMedGoogle Scholar
- Pepin M, Vitu C, Russo P, Mornex JF, Peterhans E: Maedi-visna virus infection in sheep: a review. Vet Res. 1998, 29: 341-367.PubMedGoogle Scholar
- Lyall JW, Solanky N, Tiley LS: Restricted species tropism of maedi-visna virus strain EV-1 is not due to limited receptor distribution. J Gen Virol. 2000, 81: 2919-2927.View ArticlePubMedGoogle Scholar
- Sanchez AB, Rodriguez D, Garzon A, Amorena B, Esteban M, Rodriguez JR: Visna/maedi virus Env protein expressed by a vaccinia virus recombinant induces cell-to-cell fusion in cells of different origins in the apparent absence of Env cleavage: role of glycosylation and of proteoglycans. Arch Virol. 2002, 147: 2377-2392. 10.1007/s00705-002-0874-7.View ArticlePubMedGoogle Scholar
- Bruett L, Barber SA, Clements JE: Characterization of a membrane-associated protein implicated in visna virus binding and infection. Virology. 2000, 271: 132-141. 10.1006/viro.2000.0309.View ArticlePubMedGoogle Scholar
- Dalziel RG, Hopkins J, Watt NJ, Dutia BM, Clarke HA, McConnell I: Identification of a putative cellular receptor for the lentivirus visna virus. J Gen Virol. 1991, 72 (Pt 8): 1905-1911. 10.1099/0022-1317-72-8-1905.View ArticlePubMedGoogle Scholar
- Hovden AO, Sommerfelt MA: The influence of CD4 and CXCR4 on maedi-visna virus-induced syncytium formation. APMIS. 2002, 110: 697-708. 10.1034/j.1600-0463.2002.1101003.x.View ArticlePubMedGoogle Scholar
- Crane SE, Buzy J, Clements JE: Identification of cell membrane proteins that bind visna virus. J Virol. 1991, 65: 6137-6143.PubMed CentralPubMedGoogle Scholar
- Lifson J, Coutre S, Huang E, Engleman E: Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. J Exp Med. 1986, 164: 2101-2106. 10.1084/jem.164.6.2101.View ArticlePubMedGoogle Scholar
- McGreal EP, Miller JL, Gordon S: Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol. 2005, 17: 18-24. 10.1016/j.coi.2004.12.001.View ArticlePubMedGoogle Scholar
- Linehan SA, Martinez-Pomares L, Stahl PD, Gordon S: Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med. 1999, 189: 1961-1972. 10.1084/jem.189.12.1961.PubMed CentralView ArticlePubMedGoogle Scholar
- Kerrigan AM, Brown GD: C-type lectins and phagocytosis. Immunobiology. 2009, 214: 562-575. 10.1016/j.imbio.2008.11.003.PubMed CentralView ArticlePubMedGoogle Scholar
- Lew DB, Songu-Mize E, Pontow SE, Stahl PD, Rattazzi MC: A mannose receptor mediates mannosyl-rich glycoprotein-induced mitogenesis in bovine airway smooth muscle cells. J Clin Invest. 1994, 94: 1855-1863. 10.1172/JCI117535.PubMed CentralView ArticlePubMedGoogle Scholar
- Condaminet B, Peguet-Navarro J, Stahl PD, Dalbiez-Gauthier C, Schmitt D, Berthier-Vergnes O: Human epidermal Langerhans cells express the mannose-fucose binding receptor. Eur J Immunol. 1998, 28: 3541-3551. 10.1002/(SICI)1521-4141(199811)28:11<3541::AID-IMMU3541>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Shepherd VL, Tarnowski BI, McLaughlin BJ: Isolation and characterization of a mannose receptor from human pigment epithelium. Invest Ophthalmol Vis Sci. 1991, 32: 1779-1784.PubMedGoogle Scholar
- Ezekowitz RA, Sastry K, Bailly P, Warner A: Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med. 1990, 172: 1785-1794. 10.1084/jem.172.6.1785.View ArticlePubMedGoogle Scholar
- Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE, Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B, Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P: Initial sequencing and comparative analysis of the mouse genome. Nature. 2002, 420: 520-562. 10.1038/nature01262.View ArticlePubMedGoogle Scholar
- Nonneman D, Rohrer GA: Comparative mapping of human chromosome 10 to pig chromosomes 10 and 14. Anim Genet. 2004, 35: 338-343. 10.1111/j.1365-2052.2004.01165.x.View ArticlePubMedGoogle Scholar
- Gazi U, Martinez-Pomares L: Influence of the mannose receptor in host immune responses. Immunobiology. 2009, 214: 554-561. 10.1016/j.imbio.2008.11.004.View ArticlePubMedGoogle Scholar
- Stahl PD, Ezekowitz RA: The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol. 1998, 10: 50-55. 10.1016/S0952-7915(98)80031-9.View ArticlePubMedGoogle Scholar
- Trujillo JR, Rogers R, Molina RM, Dangond F, McLane MF, Essex M, Brain JD: Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA. 2007, 104: 5097-5102. 10.1073/pnas.0611263104.PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez-Pomares L, Reid DM, Brown GD, Taylor PR, Stillion RJ, Linehan SA, Zamze S, Gordon S, Wong SY: Analysis of mannose receptor regulation by IL-4, IL-10, and proteolytic processing using novel monoclonal antibodies. J Leukoc Biol. 2003, 73: 604-613. 10.1189/jlb.0902450.View ArticlePubMedGoogle Scholar
- Sargan DR, Bennet ID, Cousens C, Roy DJ, Blacklaws BA, Dalziel RG, Watt NJ, McConnell I: Nucleotide sequence of EV1, a British isolate of maedi-visna virus. J Gen Virol. 1991, 72 (Pt 8): 1893-1903. 10.1099/0022-1317-72-8-1893.View ArticlePubMedGoogle Scholar
- Glaria I, Reina R, Crespo H, de Andrés X, Ramirez H, Biescas E, Pérez MM, Badiola J, Lujan L, Amorena B, de Andrés D: Phylogenetic analysis of SRLV sequences from an arthritic sheep outbreak demonstrates the introduction of CAEV-like viruses among Spanish sheep. Vet Microbiol. 2009, 138: 156-162. 10.1016/j.vetmic.2009.03.002.View ArticlePubMedGoogle Scholar
- Andresson OS, Elser JE, Tobin GJ, Greenwood JD, Gonda MA, Georgsson G, Andresdottir V, Benediktsdottir E, Carlsdottir HM, Mantyla EO: Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virology. 1993, 193: 89-105. 10.1006/viro.1993.1106.View ArticlePubMedGoogle Scholar
- Reina R, Glaria I, Benavides J, de Andrés X, Crespo H, Solano C, Perez V, Lujan L, Perez MM, Perez de la Lastra JM, Rosati S, Blacklaws B, Harkiss G, de Andrés D, Amorena B: Association of CD80 and CD86 expression levels with disease status of Visna/Maedi virus infected sheep. Viral Immunol. 2007, 20: 609-622. 10.1089/vim.2007.0071.View ArticlePubMedGoogle Scholar
- Fraisier C, Arnarson H, Barbezange C, Andresdottir V, Carrozza ML, De Andrés D, Tolari F, Rosati S, Lujan L, Pepin M, Amorena B, Harkiss G, Blacklaws B, Suzan-Monti M: Expression of the gp150 maedi visna virus envelope precursor protein by mammalian expression vectors. J Virol Methods. 2007, 146: 363-367. 10.1016/j.jviromet.2007.06.015.View ArticlePubMedGoogle Scholar
- Reed LJ, Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg. 1938, 27: 493-497.Google Scholar
- Schweizer A, Stahl PD, Rohrer J: A di-aromatic motif in the cytosolic tail of the mannose receptor mediates endosomal sorting. J Biol Chem. 2000, 275: 29694-29700. 10.1074/jbc.M000571200.View ArticlePubMedGoogle Scholar
- Meylan S, Trono D: Innate immunity against retroviral pathogens: from an ambiguous genetic self to novel therapeutic approaches. Swiss Med Wkly. 2009, 139: 706-711.PubMedGoogle Scholar
- Maingat F, Viappiani S, Zhu Y, Vivithanaporn P, Ellestad KK, Holden J, Silva C, Power C: Regulation of lentivirus neurovirulence by lipopolysaccharide conditioning: suppression of CXCL10 in the brain by IL-10. J Immunol. 2010, 184: 1566-1574. 10.4049/jimmunol.0902575.View ArticlePubMedGoogle Scholar
- Napper CE, Dyson MH, Taylor ME: An extended conformation of the macrophage mannose receptor. J Biol Chem. 2001, 276: 14759-14766. 10.1074/jbc.M100425200.View ArticlePubMedGoogle Scholar
- Llorca O: Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci. 2008, 65: 1302-1310. 10.1007/s00018-007-7497-9.View ArticlePubMedGoogle Scholar
- Lai J, Bernhard OK, Turville SG, Harman AN, Wilkinson J, Cunningham AL: Oligomerization of the macrophage mannose receptor enhances gp120-mediated binding of HIV-1. J Biol Chem. 2009, 284: 11027-11038. 10.1074/jbc.M809698200.PubMed CentralView ArticlePubMedGoogle Scholar
- Su Y, Royle L, Radcliffe CM, Harvey DJ, Dwek RA, Martinez-Pomares L, Rudd PM: Detailed N-glycan analysis of mannose receptor purified from murine spleen indicates tissue specific sialylation. Biochem Biophys Res Commun. 2009, 384: 436-443. 10.1016/j.bbrc.2009.04.159.View ArticlePubMedGoogle Scholar
- Autenrieth SE, Autenrieth IB: Variable antigen uptake due to different expression of the macrophage mannose receptor by dendritic cells in various inbred mouse strains. Immunology. 2009, 127: 523-529. 10.1111/j.1365-2567.2008.02960.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Wright AK, Rao S, Range S, Eder C, Hofer TP, Frankenberger M, Kobzik L, Brightling C, Grigg J, Ziegler-Heitbrock L: Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. J Leukoc Biol. 2009, 86: 479-489. 10.1189/jlb.1108699.View ArticlePubMedGoogle Scholar
- Reddy PG, Sapp WJ, Heneine W: Detection of caprine arthritis-encephalitis virus by polymerase chain reaction. J Clin Microbiol. 1993, 31: 3042-3043.PubMed CentralPubMedGoogle Scholar
- Harris N, Peters LL, Eicher EM, Rits M, Raspberry D, Eichbaum QG, Super M, Ezekowitz RA: The exon-intron structure and chromosomal localization of the mouse macrophage mannose receptor gene Mrc1: identification of a Ricin-like domain at the N-terminus of the receptor. Biochem Biophys Res Commun. 1994, 198: 682-692. 10.1006/bbrc.1994.1099.View ArticlePubMedGoogle Scholar
- Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O: DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood. 2004, 103: 2648-2654. 10.1182/blood-2003-07-2532.View ArticlePubMedGoogle Scholar
- Pollicita M, Schols D, Aquaro S, Peumans WJ, Van Damme EJ, Perno CF, Balzarini J: Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. Virology. 2008, 370: 382-391. 10.1016/j.virol.2007.08.033.View ArticlePubMedGoogle Scholar
- Nguyen DG, Hildreth JE: Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol. 2003, 33: 483-493. 10.1002/immu.200310024.View ArticlePubMedGoogle Scholar
- Le Cabec V, Emorine LJ, Toesca I, Cougoule C, Maridonneau-Parini I: The human macrophage mannose receptor is not a professional phagocytic receptor. J Leukoc Biol. 2005, 77: 934-943. 10.1189/jlb.1204705.View ArticlePubMedGoogle Scholar
- Bird P, Reyburn HT, Blacklaws BA, Allen D, Nettleton P, Yirrell DL, Watt N, Sargan D, McConnell I: The restricted IgG1 antibody response to maedi visna virus is seen following infection but not following immunization with recombinant gag protein. Clin Exp Immunol. 1995, 102: 274-280. 10.1111/j.1365-2249.1995.tb03777.x.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.